Similar articles for PMID: 15324515

Year	Number of Results
1999	3
2000	7
2001	5
2002	7
2003	8
2004	14
2005	7
2006	5
2007	10
2008	10
2009	11
2010	5
2011	7
2012	7
2013	2
2014	6
2015	2
2016	8
2017	6
2018	9
2019	6
2020	4
2022	3
2023	3
2024	1

1

Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.

Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA. Palmer AJ, et al. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S41-51. doi: 10.1185/030079904X2015. Curr Med Res Opin. 2004. PMID: 15324515

2

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP. Plosker GL, et al. Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.

3

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.

Salas M, Ward A, Caro J. Salas M, et al. Clin Ther. 2002 Oct;24(10):1690-705. doi: 10.1016/s0149-2918(02)80072-8. Clin Ther. 2002. PMID: 12462297

4

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group. Raskin P, et al. Diabetes Care. 2003 Jul;26(7):2063-8. doi: 10.2337/diacare.26.7.2063. Diabetes Care. 2003. PMID: 12832314 Clinical Trial.

5

Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.

Baron MA. Baron MA. Diabetes Care. 2003 Dec;26(12):3361-2; author reply 3362-3. doi: 10.2337/diacare.26.12.3361-a. Diabetes Care. 2003. PMID: 14633839 No abstract available.

6

Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, Spinas GA. Palmer AJ, et al. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S53-8. doi: 10.1185/030079903125002611. Curr Med Res Opin. 2004. PMID: 15324516

7

Meglitinide analogues for type 2 diabetes mellitus.

Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Black C, et al. Cochrane Database Syst Rev. 2007 Apr 18;2007(2):CD004654. doi: 10.1002/14651858.CD004654.pub2. Cochrane Database Syst Rev. 2007. PMID: 17443551 Free PMC article. Review.

8

Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.

Ramsdell JW, Braunstein SN, Stephens JM, Bell CF, Botteman MF, Devine ST. Ramsdell JW, et al. Pharmacoeconomics. 2003;21(11):819-37. doi: 10.2165/00019053-200321110-00005. Pharmacoeconomics. 2003. PMID: 12859222

9

Modeling the efficiency of reaching a target intermediate end point: a case study in type 2 diabetes in the United States.

Caro JJ, Salas M, O'Brien JA, Ishak K, Sung J, Raggio G. Caro JJ, et al. Value Health. 2004 Jan-Feb;7(1):13-21. doi: 10.1111/j.1524-4733.2004.71249.x. Value Health. 2004. PMID: 14720127 Free article.

10

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group. Rosenstock J, et al. Diabetes Care. 2004 Jun;27(6):1265-70. doi: 10.2337/diacare.27.6.1265. Diabetes Care. 2004. PMID: 15161773 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

144 results

Results by year